Skip to main content
Clinical Trials/DRKS00000304
DRKS00000304
Completed
Phase 4

Clinical effectiveness of the newer antipsychotic compounds olanzapine, quetiapine and aripiprazole in comparison with low dose conventional antipsychotics (haloperidol and flupentixol) in patients with schizophrenia - NeSSy (Neuroleptic Strategy Study)

niversität BremenKompetenzzentrum für Klinische Studien Bremen, Biometrie0 sites149 target enrollmentDecember 21, 2009

Overview

Phase
Phase 4
Intervention
Not specified
Conditions
F20
Sponsor
niversität BremenKompetenzzentrum für Klinische Studien Bremen, Biometrie
Enrollment
149
Status
Completed
Last Updated
last year

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
December 21, 2009
End Date
March 31, 2014
Last Updated
last year
Study Type
Interventional
Sex
All

Investigators

Sponsor
niversität BremenKompetenzzentrum für Klinische Studien Bremen, Biometrie

Eligibility Criteria

Inclusion Criteria

  • Patients with schizophrenia, age 18\-65, necessity to establish new or change antipsychotic treatment due to unsatisfying results or side effects.

Exclusion Criteria

  • Acute suicidal tendency, Einwilligungsvorbehalt (BGB) or Unterbringung (PsychKG), organic psychosis, history of malignant neuroleptic syndrome, QTc interval greater than or equal to 0\.5 s / history of congenital QTc prolongation.

Outcomes

Primary Outcomes

Not specified

Similar Trials